Keytruda pembrolizumab: Additional Phase II data

Data from 92 evaluable patients with recurrent or metastatic SCCHN who progressed on platinum-based therapy and cetuximab in the open-label Phase II KEYNOTE-055 trial

Read the full 249 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE